Company / SG&A Expense
Cullinan Therapeutics, Inc. SG&A Expense History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$54.0M
FY2024
5-year range
$17.1M / $54.0M
FY2020-FY2024
Trend
+27.1%
vs FY2023
Sector context
#153 of 213
Health Care
What the data says
At $54M, Cullinan Therapeutics, Inc.'s sg&a expense ranks #61 of 213 in the Health Care sector. SG&A Expense has increased for 3 consecutive years, from $17M in FY2021 to $54M in FY2024.
Based on SEC 10-K filings.
$54M in FY2024 with a 3-year CAGR of +46.7%.
Increased from $40M to $54M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +46.7%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#61 of 213 in Health CareTop 28% of 213This company $54.0M Sector average $722.3M
▼
-92.5% below sector average
Key checks
Key Insights
- Cullinan Therapeutics, Inc.'s sg&a expense has grown for 3 consecutive years.
- 3-year CAGR of +46.7%, indicating consistent growth.
- In FY2024, sg&a expense increased 27.1% year-over-year.
- Ranks #153 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 7.33 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $54.0M | +27.1% |
| FY2023 | $42.5M | +5.7% |
| FY2022 | $40.2M | +134.7% |
| FY2021 | $17.1M | +0.0% |
| FY2020 | $17.1M | - |
As of FY2024 · SEC 10-K · Updated Jul 2, 2026